Selling a cannabis cultivation facility in Canada

Unlike most business sales, the day the deal closes and the day the buyer can actually run the operation are not the same day. The federal licence sits between the two, and the entire sale needs to be sequenced around the gap rather than treated as an afterthought once the purchase agreement is signed.

The licence amendment is the critical path

Every ‘responsible person’ and certain key personnel with production or security oversight must undergo and maintain a Health Canada security clearance, and this is assessed on the specific individuals proposed, not on the buyer’s company in the abstract. Sellers who push the buyer to identify their actual proposed principals early — rather than leaving it vague until closer to closing — let that clearance process start sooner, and it is routinely the slowest step in the entire transaction.

Structuring the deal around a slow, uncertain approval

Making closing conditional on the licence amendment being granted, and thinking through what interim arrangement (if any) governs the period between signing and that approval, is a genuine legal negotiation rather than boilerplate. Disclosure schedules should spell out the current licence conditions and compliance history in detail, since the buyer’s own application will be assessed partly against that record.

The provincial wholesaler relationship survives only if it wants to

The provincial wholesale distributor — Ontario’s OCS is one example — has its own discretion over whether to keep buying from the facility once ownership changes. Sellers should not assume that relationship simply carries over and should raise the change with the distributor in parallel with the Health Canada process rather than after closing, when there is far less room to fix a problem.

What buyers will ask for

Expect requests for canopy utilization and yield history, the current physical-security compliance status against Health Canada’s standard, the wholesale contract’s terms and volume history, and a clean record on any compliance inspection tied to a prior ownership change. A seller with these organized moves the buyer’s own clearance and financing conversations forward faster.

Facility compliance before you list

A facility that’s overdue for a compliance inspection, or carrying an open municipal zoning or odour complaint, is better addressed before marketing the business than left for the buyer to discover, since either can trigger a licence review at exactly the point a change of control is also under review — compounding delay rather than running in parallel with it.

What commonly delays closing

Health Canada declining or taking longer than expected to clear a proposed principal, the provincial wholesaler declining to continue the relationship, or a compliance inspection triggered by the ownership change turning up a finding are the recurring reasons a cannabis facility sale slips its expected closing date. None of these make the deal impossible — they simply need to be planned around rather than discovered under time pressure.

Selling to an already-licensed buyer moves differently than selling to a newcomer

Who’s on the other side of the table changes how the Health Canada process actually runs, not just how fast it feels. A buyer that already holds a licence elsewhere, with principals already cleared on another facility, is often clearing the change-of-control review faster than a first-time entrant would, because Health Canada is assessing individuals it may already have clearance history for rather than starting from a blank file. A vertically integrated buyer folding the facility into a larger cultivation-and-processing business may also want different representations in the purchase agreement than an individual buyer would — around how the facility’s genetics, standard operating procedures and existing wholesale relationships are expected to integrate into their broader operation, not just around the sale price. Sellers who ask a prospective buyer directly about their existing licence and clearance status, early, get a far more realistic read on timeline than sellers who wait to find out during the Health Canada review itself.

Disclosing the compliance file honestly protects the sale, not just the seller

Because the buyer’s own application is assessed partly against the facility’s compliance record, an incomplete or overly favourable disclosure schedule doesn’t just create legal risk for the seller — it can actively slow down or jeopardize the buyer’s own clearance, since gaps that surface later during Health Canada’s review read worse than the same issue disclosed upfront and explained. A seller who discloses a past inspection finding along with the corrective action actually taken generally fares better than one who leaves it out and hopes it doesn’t surface, because Health Canada’s own review has access to the facility’s inspection history regardless of what the purchase agreement says.

Keep the genetics and SOPs moving even if the licence stalls

Because the licence amendment can take considerably longer than the rest of the deal, it’s worth structuring the purchase agreement to let genetics, standard operating procedures and other non-licence-dependent assets transfer, or at least be fully documented and escrowed, early — rather than bundling everything into one closing gated by Health Canada’s timeline. This doesn’t get around the fact that the buyer can’t legally cultivate until the amendment clears, but it does mean the deal isn’t hostage to the licence review for every single component of what’s being sold.